Dünya üzrə etibarlı mənbələrdən Drug haqqında ən son xəbərlər və yeniliklər.
A new study reported by Reuters suggests that GLP-1 receptor agonists, a widely used class of diabetes and weight-loss drugs, may be associated with a lower risk of developing 10 cancers tied to…
The U.S. Food and Drug Administration has granted accelerated approval to a new obesity treatment from Novo Nordisk, giving the Danish drugmaker another major regulatory win in a fast-growing market.…
A new clinical trial has found that an experimental treatment may ease symptoms for people living with treatment-resistant depression, a condition that can persist even after patients try multiple…
Pfizer said its experimental obesity treatment produced an average weight loss of 18% after 68 weeks in a late-stage clinical trial, a result that puts the company closer to joining a fast-growing…
A large analysis of electronic health records suggests that GLP-1 receptor agonists, a class of drugs widely used for diabetes and weight loss, may be associated with lower rates of several cancers…
GSK said it will acquire privately held biotech company IDRx in a transaction valued at up to $1.15 billion, strengthening its oncology pipeline with a drug candidate aimed at gastrointestinal…
The U.S. Food and Drug Administration has approved the first generic version of Wegovy, the obesity treatment made by Novo Nordisk. The decision could widen access to a drug that has become widely…
President Donald Trump signed an executive order on Friday directing federal agencies to pursue steps meant to reduce prescription drug prices, including costs for Medicare patients. The move is the…
Pfizer says its experimental obesity pill produced an average 15% reduction in body weight over 52 weeks in a phase 3 trial, a result that could strengthen the company’s push into the fast-growing…
Pfizer said its investigational oral antibiotic gepotidacin delivered strong results in a pivotal phase 3 trial involving uncomplicated urinary tract infections caused by resistant bacteria. The…
Eli Lilly and Novo Nordisk are confronting a new challenge to their dominance in the fast-growing weight-loss drug market: mounting pressure from generic manufacturers that could bring copycat…
The U.S. Food and Drug Administration has approved a generic version of a widely used diabetes medication, a move that could expand access and reduce costs for patients who rely on the drug. Generic…
